MARKET

DTIL

DTIL

Precision Biosciences
NASDAQ
5.15
-0.08
-1.44%
Closed 18:44 05/13 EDT
OPEN
5.22
PREV CLOSE
5.22
HIGH
5.39
LOW
5.10
VOLUME
43.51K
TURNOVER
--
52 WEEK HIGH
13.44
52 WEEK LOW
3.610
MARKET CAP
40.60M
P/E (TTM)
4.942
1D
5D
1M
3M
1Y
5Y
1D
Akoya Biosciences (AKYA) Reports Q1 Loss, Misses Revenue Estimates
NASDAQ · 1d ago
Weekly Report: what happened at DTIL last week (0505-0509)?
Weekly Report · 2d ago
Precision BioSciences Inc <DTIL.OQ> expected to post a loss of $1.72 a share - Earnings Preview
Reuters · 4d ago
Optimistic Buy Rating for Precision BioSciences Driven by Promising Safety Data and Potential Functional Cure for HBV
TipRanks · 5d ago
Press Release: Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025
Dow Jones · 5d ago
Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025
Barchart · 6d ago
PRECISION BIOSCIENCES ANNOUNCES PRESENTATION OF INITIAL SAFETY DATA FROM THE PHASE 1 ELIMINATE-B TRIAL EVALUATING PBGENE-HBV AT THE 2025 EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER CONGRESS (EASL)
Reuters · 6d ago
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
NASDAQ · 05/06 21:15
More
About DTIL
More
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
Recently
Symbol
Price
%Change

Webull offers Precision BioSciences Inc stock information, including NASDAQ: DTIL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DTIL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DTIL stock methods without spending real money on the virtual paper trading platform.